CASI Pharmaceuticals Q1 2025 Earnings Report

CASI Pharmaceuticals EPS Results

• Actual EPS: -$0.69
• Consensus EPS: -$0.61
• Beat/Miss: Missed by -$0.08
• One Year Ago EPS: N/A

CASI Pharmaceuticals Revenue Results

• Actual Revenue: $6.24 million
• Expected Revenue: $7.39 million
• Beat/Miss: Missed by -$1.15 million
• YoY Revenue Growth: N/A

CASI Pharmaceuticals Announcement Details

• Quarter: Q1 2025
• Date: 5/16/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

CASI Pharmaceuticals (NASDAQ:CASI), Inc. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of innovative therapies in oncology and immunology. The company leverages a combination of small‐molecule targeted drugs and biologics to address high‐unmet medical needs in cancer and autoimmune diseases. CASI’s R&D efforts emphasize the discovery and advancement of compounds that modulate key signaling pathways, with a goal of delivering differentiated treatment options to patients worldwide.

The company’s lead clinical candidate is famitinib, a multi‐targeted tyrosine kinase inhibitor that has been evaluated in various solid tumors, including gastric, breast and renal cancers. In addition to famitinib, CASI is advancing an immuno-oncology portfolio that includes checkpoint inhibitors and novel immune modulators designed to enhance antitumor responses. Preclinical programs focus on next‐generation molecules with potential applications in both oncology and inflammatory disorders, building on the company’s proprietary discovery platform.

Founded by a team of biotech entrepreneurs and scientists, CASI Pharmaceuticals is headquartered in Beijing, with research and development operations in Shanghai and a presence in North America to support global clinical activities. The company has established strategic partnerships with academic institutions and contract research organizations to accelerate its clinical trials and expand its pipeline. CASI’s leadership team comprises industry veterans with extensive experience in drug development and regulatory affairs, guiding the company through key milestones as it pursues regulatory approvals and commercial readiness.